Fibrostenosis Focused Therapeutics - RFP
Supports translational research to develop non-surgical therapies for fibrosis in IBD, advancing clinically grounded products toward commercialization and patient impact.
Funder: Crohn's and Colitis Foundation
Due Dates: May 31, 2026 (Preproposal) | June 30, 2026 (LOI) | August 14, 2026 (Full proposal)
Funding Amounts: Up to $450,000 for one year; possible renewal for additional years if milestones are met; indirect costs capped at 10%.
Summary: Funds development of non-surgical therapeutic solutions for fibrosis in IBD, supporting translational and product-oriented research based on clinical or published human evidence.
Key Information: Preproposal submission is required before LOI and full proposal; international and US applicants eligible.
Description
The Crohn's & Colitis Foundation invites proposals for the development of innovative, non-surgical therapies targeting fibrosis in inflammatory bowel disease (IBD), including Crohn’s disease and ulcerative colitis. This program aims to address the significant unmet need for effective treatments for fibrotic complications in IBD, supporting translational and product development efforts grounded in clinical observations or published human IBD evidence. The Foundation is particularly interested in projects evaluating the modulation of specific fibrotic pathways or employing multidisciplinary strategies, with the goal of advancing products toward commercialization and clinical impact.
